Ocvirk, J., & Rebersek, M. (2008). Managing cutaneous side effects with K1 vitamin creme reduces cutaneous toxicities induced by cetuximab. Journal of Clinical Oncology, 26(15, Suppl.), 20750.
Patients receiving cetuximab were seen weekly and started with topical 0.1% vitamin K1 cream with urea applied BID, beginning with first noted rash.
Department of Medical Oncology at the Institute of Oncology Ljubljana in Slovenia
This was a case report series.
Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.
Rash was improved in all patients after eight to 18 days of initiating cream with urea and 0.1% vitamin K1 applied BID.
Application of cream with urea and 0.1% vitamin K1 BID was effective in managing cetuximab-induced rash.